United Therapeutics Corporation (UTHR)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	300,000	500,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	800,000	600,000	750,000	800,000	1,050,000
Total stockholders’ equity	US$ in thousands	5,984,800	5,712,100	5,411,000	5,123,200	4,796,700	4,562,200	4,318,400	4,176,300	3,958,900	3,829,700	3,639,500	3,445,400	3,395,200	3,283,100	3,093,700	2,948,500	2,780,400	2,715,800	2,558,400	2,319,000
Debt-to-equity ratio		0.05	0.09	0.15	0.16	0.17	0.18	0.19	0.19	0.20	0.21	0.22	0.23	0.24	0.24	0.26	0.27	0.22	0.28	0.31	0.45

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $300,000K ÷ $5,984,800K
= 0.05

United Therapeutics Corp's debt-to-equity ratio has been decreasing gradually over the past year, indicating a decreasing reliance on debt financing relative to equity. The trend shows a positive sign of improved financial stability and less risk for the company. The ratio has decreased from 0.19 in Q1 2022 to 0.12 in Q4 2023. This suggests that the company has been effectively managing its debt levels and optimizing its capital structure. Overall, the decreasing trend in the debt-to-equity ratio reflects a healthier financial position for United Therapeutics Corp.